Description: The American Academy of Actuaries is engaged in several projects that proactively examine the future status of the Medicare Program. This session presents the findings that have resulted from these efforts. From the Record of the Society of Actuaries, Vol. 24, No. 2.

Description: This panel discussion session focuses on the effects of consumerism and regulation on the health insurance industry in the United States and Canada. Includes legislation on non-discrimination, mandated benefits and special coverage such as credit & specified diseases. From Record of the SOA 1979 Vol. 5 No. 3

Description: This session from the 1995 SOA Vancouver Meeting discusses and debates the merits and implications of community rating and guaranteed issue state requirements. State examples are discussed. From the Record of the Society of Actuaries, Vol. 21, No. 3a.

Description: This session explores the use of genetic testing in the health insurance business and protecting privacy. From the Record of the Society of Actuaries, Volume 28, No. 2, Session 130

Description: This session discusses the merits of the Small Business Health Fairness Act [an amendment to ERSIA] and the implications of associations sponsoring health plans for small employer groups. From the Record of the Society of Actuaries, Volume 30, No. 1, Session 35

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: Savings from biosimilars have accelerated significantly in the past few years. There has been a number of relatively recent biosimilar launches that can help to shape our expectations of the financial impact that could result from this year’s big event. Savings from biosimilars have accelerated significantly in the past few years. There has been a number of relatively recent biosimilar launches that can help to shape our expectations of the financial impact that could result from this year’s big event.

Description: Discussion of the following topics pertaining to disability income and other health insurance: 1. What portions of the loss of income and of the expenses incurred are properly insurable? 2. What special problems are encountered in providing suitable coverage for the following: a Employees and dependents eligible under Group plans b Individuals employed or not employed and their dependents ineligible under Group plans c Aged persons. 3. Methods for companies to meet the problems of overinsurance arising from duplication of coverage or from other causes?

Description: This article discusses of the Federal Employees' Health Benefits Program. Specifically addressed were the flexible features, the political environment and changes being considered.

Description: This session is about regulatory constraints and the role the NAIC is playing to help facilitate 24-hour programs, plan design issues, the use of managed care, coverage as part of a workers' compensation plan versus coverage of health care outside of the workers' compensation system. From Record of Society of Actuaries Vol. 18, No. 4A.